{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:50:19Z","timestamp":1791348619955,"version":"4.3.1"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The impact of extent of resection of the primary tumor on outcomes in patients with high-risk neuroblastoma (HRNB) remains uncertain. We evaluated this issue in patients with HRNB treated on a prospective trial of multimodality therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of Background Data:<\/jats:title>\n                    <jats:p>Patients with HRNB enrolled on COG ANBL0532 who underwent surgical resection of their primary tumor during induction were included. Extent of resection was defined by the surgeon as complete excision (CE) if \u226590% of the tumor was resected, and incomplete excision (IE) if &lt;90% was resected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Overall and event-free survival (OS, EFS) were estimated from time of surgery and compared between groups with a log-rank test. Cumulative incidence of local progression (CILP) was estimated using competing risks analysis and compared between groups with Gray test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 326 patients met inclusion criteria (CE=269, IE=57). Demographics were comparable between groups. CE was more likely in patients with adrenal tumors,\n                      <jats:italic toggle=\"yes\">MYCN<\/jats:italic>\n                      -amplified tumors, and those without image-defined risk factors (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). Patients with CE had improved 5-year EFS (50.3%\u00b13.3% vs. 31.0%\u00b16.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0016) and OS (61.8%\u00b13.1% vs. 41.1%\u00b16.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0094) and decreased 5-year CILP (12.8%\u00b12.1% vs. 24.8%\u00b15.8%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0306). When stratified by extent of resection and autologous stem-cell transplant type, patients with CE randomized to tandem transplant had the highest 5-year EFS, while patients with IE and single transplant had inferior outcomes (57.9\u00b15.5% vs. 18.5\u00b111.8%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0411). Among patients who received immunotherapy CE was associated with improved 5-year EFS. There was no difference in surgical complications between IE and CE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CE of the primary tumor was associated with significantly higher EFS, OS, and decreased CILP, with no increase in surgical complications. As part of a comprehensive, multimodal treatment strategy, complete primary tumor resection when feasible is a critical component of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/sla.0000000000007228","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:00:18Z","timestamp":1791345618000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Extent of Surgical Resection on Survival in Patients With High-risk Neuroblastoma"],"prefix":"10.1097","author":[{"given":"Christa N.","family":"Grant","sequence":"first","affiliation":[{"name":"Westchester Medical Center, Department of Surgery, Division of Pediatric Surgery, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Naranjo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Children\u2019s Oncology Group (COG) Statistics and Data Center, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan F.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group Statistics and Data Center, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Diller","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin G.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California Davis Medical Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Geiger","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Nationwide Children\u2019s Hospital, Toledo, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Doski","sequence":"additional","affiliation":[{"name":"University of Texas Health Sciences Center San Antonio, Departments of Surgery and Pediatrics, Division of Pediatric Surgery, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne A.","family":"Haas-Kogan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mass General Brigham, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed G.","family":"Nuchtern","sequence":"additional","affiliation":[{"name":"Division of Global Surgery and Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Davidoff","sequence":"additional","affiliation":[{"name":"Department of Surgery, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"DuBois","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center and Department of Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave R.","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Surgery, Children\u2019s Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika A.","family":"Newman","sequence":"additional","affiliation":[{"name":"University of Michigan, C.S. Mott Children\u2019s Hospital, Section of Pediatric Surgery, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,7]]},"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:00:19Z","timestamp":1791345619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/SLA.0000000000007228"}},"subtitle":["A Report From Children\u2019s Oncology Group ANBL0532"],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000007228","relation":{},"ISSN":["0003-4932","1528-1140"],"issn-type":[{"value":"0003-4932","type":"print"},{"value":"1528-1140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"2026-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}